Welcome to our dedicated page for Armata Pharmctcl news (Ticker: ARMP), a resource for investors and traders seeking the latest updates and insights on Armata Pharmctcl stock.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) generates frequent news as a clinical-stage biotechnology company developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. News coverage of Armata often centers on its lead intravenous phage cocktail AP-SA02 for complicated Staphylococcus aureus bacteremia and its multi-phage candidate AP-PA02 targeting Pseudomonas aeruginosa in chronic respiratory disease.
Readers following ARMP news can expect detailed updates on clinical trial milestones, including topline data, late-breaking conference presentations, and regulatory interactions. Recent announcements have described positive Phase 1b/2a results from the diSArm study of AP-SA02, higher and earlier cure rates compared with antibiotics alone, and an End-of-Phase 2 written response from the U.S. Food and Drug Administration supporting advancement of AP-SA02 into a planned Phase 3 superiority study in complicated S. aureus bacteremia.
Armata’s news flow also includes information on manufacturing and infrastructure, such as the formal commissioning of its cGMP phage manufacturing facility in Los Angeles, California, which is intended to support late-stage clinical development and potential commercial production. Financial and corporate updates appear in quarterly results releases, describing grant and award revenue from the U.S. Department of Defense, secured credit agreements with Innoviva Strategic Opportunities LLC, and at-the-market equity offering arrangements.
Additional coverage highlights scientific publications and conference participation, including structural biology work on phage Pa223 in the Journal of Molecular Biology and presentations at IDWeek, the Military Health System Research Symposium, and the Evergreen Phage Meeting. For investors, clinicians, and researchers, this news page offers a centralized view of Armata’s progress in phage therapy, regulatory dialogue, funding developments, and manufacturing readiness. Bookmark this page to review ongoing ARMP press releases, SEC-linked disclosures, and other company communications as they are released.
Summary not available.
Summary not available.
Summary not available.
Armata Pharmaceuticals, a biotechnology firm focused on bacteriophage therapeutics, announced its fourth-quarter and full-year 2022 financial results on March 16, 2023. Key highlights include positive topline results from the SWARM-P.a. Phase 1b/2a trial for AP-PA02 in cystic fibrosis patients, which supports its progression to Phase 2b. The company also initiated the Phase 2 study for non-cystic fibrosis bronchiectasis and advanced its AP-SA02 program. Financially, Armata reported Q4 2022 grant revenue of $1.1 million and a loss from operations of $10.3 million, an increase from the previous year. The company concluded the year with $14.9 million in cash.
Armata Pharmaceuticals (ARMP) reported positive topline results from the Phase 1b/2a SWARM-P.a. trial for its inhaled phage therapy, AP-PA02, targeting chronic pulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients. The data revealed that AP-PA02 was well-tolerated, with mild adverse events similar to the placebo group. Treatment showed a trend towards bacterial load reduction, particularly in subjects with higher exposure. Additionally, Armata announced the initiation of its Tailwind trial for NCFB patients, marking its third active clinical program and optimizing dosing based on previous trial insights. This positions Armata to potentially establish phage therapy as a novel treatment option.
Armata Pharmaceuticals announced the closing of a secured convertible credit agreement with Innoviva Strategic Opportunities, providing $30 million in gross proceeds. The company plans to utilize these funds for the clinical development of AP-PA02 and AP-SA02, along with constructing a cGMP manufacturing facility. The one-year term loan features an 8.0% interest rate and is secured by nearly all of Armata's assets. Conversion of the loan into shares will occur during qualified financing or at Innoviva's option after a resale registration statement is effective.
Armata Pharmaceuticals has completed its Phase 1b/2a SWARM-P.a. clinical trial assessing inhaled AP-PA02 for cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa infection. This milestone was noted by the company's executives, highlighting its implications for further phage therapy research. The study aims to evaluate safety, tolerability, and dosing paradigms necessary to meet microbiological endpoints, with topline data expected in Q1 2023. Armata previously received significant funding from the Cystic Fibrosis Foundation to support the development of this candidate.
Armata Pharmaceuticals (NYSE American: ARMP) will participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage, scheduled for November 30, 2022, from 10:00-10:30 AM EST. This conference will be held virtually, focusing on the company's advancements in bacteriophage therapeutics aimed at treating antibiotic-resistant infections. Armata is developing a diverse pipeline of phage candidates, particularly for Pseudomonas aeruginosa and Staphylococcus aureus, and collaborates with Merck on synthetic phage candidates.
Armata Pharmaceuticals (ARMP) reported its third quarter 2022 financial results, highlighting progress in clinical trials for its bacteriophage therapeutics. Key developments include the final enrollment phase of the SWARM-P.a. study and advancements in the AP-SA02 programs. The company recognized $1.3 million in grant revenue and expects $16.3 million in total funding from MTEC. R&D expenses rose to $8.4 million, while losses from operations increased to $(8.6) million. The company holds $25.4 million in cash as of September 30, 2022.
Armata Pharmaceuticals (ARMP) announced its Q2 2022 financial results, reporting significant advancements in bacteriophage therapeutics. The company recognized approximately $1.9 million in grant revenue and expects an additional $15 million from the Defense Health Agency. R&D expenses rose to $9 million, up from $5.2 million. Armata's operational loss increased to $9.2 million compared to $6.2 million a year prior. The company maintained a healthy cash position with $37 million in cash and equivalents. Key developments include the advancement of the AP-PA02 trial and IND approvals for the AP-SA02 program.
FAQ
What is the current stock price of Armata Pharmctcl (ARMP)?
What is the market cap of Armata Pharmctcl (ARMP)?
